Bristol Myers Offers More Yield Than Merck, With More Patent Risk

Bristol Myers Squibb and Merck offer different versions of a large-pharma income stock. Bristol Myers yielded about 4.3% in the source comparison, versus 2.4% for Merck, and used roughly 45% of free cash flow for dividends compared with Merck's 52%.

The higher current income comes with slower growth. Bristol Myers raised its dividend about 2.9% over the latest year, while Merck's increase was roughly 5.1%. A lower payout ratio can create room for future raises, but only if free cash flow remains resilient as older drugs lose exclusivity.

Bristol Myers is trying to manage that transition with a newer growth portfolio. Fiscal Q2 sales from those products increased 15% to $7.6 billion, while the legacy portfolio declined 4%. Management guided to $49 billion to $50 billion of annual revenue and about $11.4 billion of free cash flow in the source report.

Merck produced second-quarter sales of $16.6 billion, up 5%, including roughly $8.4 billion from Keytruda. That concentration supports current cash generation but creates a large patent and product-cycle risk later in the decade. Management guided to $66.3 billion to $67.3 billion of annual sales.

Bristol Myers looks stronger for immediate yield and dividend coverage. Merck has delivered faster payout growth and carries a broader valuation premium, but its dependence on Keytruda is hard to ignore. The decision is not simply 4.3% versus 2.4%. Investors should weigh Bristol Myers' debt and legacy-drug erosion against Merck's single-franchise concentration, then follow free cash flow rather than earnings alone when judging future dividend capacity.